Introduction
============

Lung cancer is one of the major causes of cancer morbidity and mortality on a global scale[@B1]. Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer cases, and its 5-year overall survival rate about 15%[@B2]. Chronic hepatitis B viral (HBV) infection is a serious global public problem: about two billion people have been infected with HBV worldwide[@B3]. However, the infection status is more severe in China, because HBV patients in China account for approximately 38% of all patients worldwide[@B4]. NSCLC patients with chronic HBV infection are common in the clinical setting. Previous studies have reported that chronic HBV infection was associated with poor prognosis in patients with nasopharyngeal carcinoma[@B5], pancreatic cancer[@B6], and NSCLC[@B7]. Thus, a distinct prognostic model is required to distinguished NSCLC patients with HBV infection from those without HBV infection.

Chronic HBV (CHB) infection could induce chronic inflammation in patients with CHB[@B8]. Inflammation has been confirmed to aid in the proliferation and survival of malignant cells, and it can promote tumor initiation and metastasis[@B9]. Previous studies have reported that serum inflammatory-based markers were significant factors for prognosis in cancer, including serum albumin (ALB)[@B10], serum C-reactive protein (CRP)[@B11], neutrophil/lymphocyte ratio (NLR)[@B12]-[@B13], and platelet/lymphocyte ratio (PLR)[@B13]. Several studies have reported that inflammation factors were biomarkers for the prognosis of NSCLC patients [@B14]-[@B16]. However, the effect of inflammation-based factors in NSCLC patients with HBV infection on survival is unclear.

There were four aims of the present retrospective study. First, we aimed to evaluate the prognostic significance of inflammation-based factors and clinicopathological characteristics in NSCLC patients with HBV infection. Secondly, we aimed to establish a prognostic model to be used for individual risk estimation at the point of diagnosis for NSCLC patients with HBV infection. Thirdly, we aimed to compare the inflammation-based prognostic model with traditional TNM (tumor, node, metastasis) staging. Finally, we aimed to calculate the prognosis scores of patients based on our prognostic model, and then according to those prognosis scores, the patients will be divided into a high risk group, an intermediate risk group, and a low risk group.

Methods and Materials
=====================

Patients and study design
-------------------------

We performed a retrospective review of NSCLC patients with chronic HBV infection. Patients first visited the Sun Yat-sen University Cancer Center (Guangzhou, China) between January 2008 and December 2010. This study was approved by the Clinical Research Ethics Committee of the Sun Yat-sen University Cancer Center, and all patients provided written informed consent at the first visit to our center. The patients included in the analysis met the following criteria: 1) NSCLC diagnosis confirmed by histopathology, were not any malignancies besides NSCLC; 2) all patients with HBsAg (+), and excluding acute hepatitis; 3) inflammation-based factors were obtained prior to anticancer treatment; 4) no liver fibrosis, steatosis and cirrhosis were detected by CT or ultrasonographic examination.

Clinical information was collected from medical records at the Cancer Center. The clinical stage of the disease was determined according to 7th edition of the AJCC TNM staging manual[@B17]. The clinical characteristics analyzed were gender, age, family history, smoking behavior, TNM stage, histological type, tumor size, and treatment. The potential prognostic factors included ALB, CRP, WBC, neutrophil, lymphocyte, platelet, NLR, PLR, and prognostic nutritional index (PNI).

The PNI was calculated by the following formula: albumin (g/L) + 5 × lymphocyte count × 10^9^/L. Patients with a PNI \> 45 were assigned a score of 0, and patients with a PNI ≤ 45 were assigned a score of 1[@B18]. The various ratios were calculated as follows: NLR = N / L; and PLR = PLT / L, N, L, and PLT were the levels of neutrophils, lymphocytes, and platelet counts, respectively, before treatment with anticancer drugs.

The patients were followed up via clinic visits and telephone interviews. The overall survival (OS) was defined as the interval between the initial diagnosis and either death of cancer or the last follow-up. All patients were followed up until death or January 2016, if still alive. The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform ([www.researchdata.org.cn](http://www.researchdata.org.cn)), with the approval RDD number as RDDA2018000615.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS software, version 19.0 (SPSS Inc., Chicago, IL, USA) and R (version 3.4.4) for Windows. Categorical variables were classified based on clinical findings. The cut-off values of WBC and neutrophil were based on biological inflammation cutoff points in clinical application[@B19], and other continuous variables were transformed into categorical variables based on the cut-off values of the X-tile program[@B20]. The Kaplan-Meier curves were used to calculate the survival rate, and the Log-rank test was used to compare them. Univariate analysis was performed to assess the significance of clinical and pathological characteristics. The Cox proportional hazards regression was used for multivariate analysis. All variables with P values less than 0.05 in the multivariable model were used to develop a dynamic prediction nomogram model. The performance of the dynamic prediction nomogram model was measured by the concordance index (C-index), and validated using 1000 bootstrap re-samplings. Comparison of the prediction accuracy between the dynamic prediction nomogram model, reported model[@B21] and traditional TNM staging systems in NSCLC patients with HBV infection were performed using the C-index[@B22] and decision curve analysis[@B23]. The difference was considered statistically significant when p \< 0.05.

Results
=======

Patient characteristics
-----------------------

In this study, a total of 203 NSCLC patients with HBV infection were enrolled. the median age was 56 years (range 27-82 years); there were 155 (76.4%) were males and 48 (23.6%) females. At the time of the last follow-up, the median OS was 33 months. The 3- and 5-year OS rates for patients were 47.3% and 32.0%, respectively. The demographic and clinical characteristics of the 203 patients are summarized in Table [1](#T1){ref-type="table"}. The following cut-off values for continuous variables were obtain using the X-tile program: age (42 years), tumor size (6.0 cm), ALB (37.6 g/L), CRP (9.5 mg/L), lymphocyte (1.8x10\^^9^/L), PLT (163x10\^^9^/L), NLR (4.30), PLR (109.5), and PNI (48.1).

Univariate analysis and multivariate Cox proportional hazards regression analysis of the overall survival
---------------------------------------------------------------------------------------------------------

The univariate analysis revealed that age, TNM stage, size, treatment, ALB, CRP, WBC, neutrophil, PLT, NLR, PLR, and PNI were associated with OS (*P* \< 0.05, Table ​2). Then the prognostic factors that were significantly associated with OS in the univariate analyses were entered into the multivariate Cox proportional hazards regression analysis of OS. The multivariate analysis showed that TNM stage (HR = 1.40, 95% CI = 1.06-1.86, *P* = 0.019), treatment (HR = 1.76, 95% CI = 1.28-2.40, *P* \< 0.001), CRP (HR = 1.76, 95% CI =1.09-2.84, *P* = 0.020), and PLT (HR = 0.43, 95% CI = 0.22-0.83, *P* = 0.012) were independently associated with OS. A forest plot shows the hazard ratios and 95% confidence intervals for OS according to the Cox proportional hazards regression analysis (Figure [1](#F1){ref-type="fig"}).

Construction and validation of dynamic prediction nomogram
----------------------------------------------------------

All of the independent predictors of OS in multivariate Cox proportional hazards regression analysis were integrated into the dynamic prediction nomogram model, and the 3- and 5-year survival probability were graphically computed based on the unique characteristics of an individual patient (Figure. 2). The models include TNM stage, CRP, PLT at diagnosis, and treatment. The C-index of the dynamic prediction nomogram model was 0.76 (95% CI = 0.72-0.80).

Each prognostic factor has a number of risk points, which can be obtained by drawing a vertical line straight up from the prognostic factor\'s corresponding value to the axis with \"Points\". To determine the 3- and 5-year OS probability of a specific patient from the \"Total Points\" which is the sum of the risk points, a vertical line can be drawn towards the axis labeled "3- and 5-Year Overall Survival Probability". For example (Figure. 2), we will consider a patient had a TNM stage III (31 points) with a CRP level of 118.7 mg/L (80 points), a PLT of 394x10\^9/L (16.5 points), and the patient has undergone surgery (6.5 points). Thus, the sum of the total risk points was 134, and a vertical line can be drawn down to the \"3- and 5-year survival probability\" axis. For this patient, the 3-year survival probability is 35.6%, and the 5-year survival probability is 20.0%.

Comparison of the predictive accuracy between current dynamic nomogram, reported nomogram and conventional staging systems
--------------------------------------------------------------------------------------------------------------------------

Comparison of the predictive accuracy of current nomogram model with reported nomogram model and conventional staging systems were done using C-index and decision curve analysis for 3- and 5-year survival. A larger C-index and area under the curve of the decision curve indicates a more accurate prognostic stratification. The C-index of the current nomogram model was 0.76 (95% CI = 0.72-0.80), which was significantly better than the TNM staging systems 0.70 (95% CI = 0.66-0.74, Table [3](#T3){ref-type="table"}). There was no statistical difference between the current model and reported model (0.77, 95% CI = 0.63-0.81). Decision curve analysis for 3- and 5-year survival (Figure. 3A, 3B, respectively) revealed that the predictive accuracy of the current nomogram (black dotted line) had a higher net benefit than the TNM staging systems (green dotted line). The predictive accuracy of the current nomogram model keeping almost the same accuracy as previous reported one (red dotted line).

Performance of the dynamic nomogram in stratifying patient risk
---------------------------------------------------------------

All patients were further stratified by the total points (TPS) of the dynamic prediction nomogram model for OS analysis. We divided the patients into three groups: low risk (total points \[TPS\] ≤ 107, 90 patients), intermediate risk (107\< TPS ≤ 149, 89 patients) and high risk (TPS \> 149, 24 patients). The Kaplan-Meier plot showing the OS for patients of the three subgroups indicates that the high risk group is linked to a poor prognosis (Figure. 4). The differences between OS rates were significant (*P* \< 0.001).

Discussion
==========

In this study, we utilized the advantages of the ability of dynamic nomogram with integration of inflammation-based factors and clinicopathological characteristics to establish an effective survival prognostic model for NSCLC patients with HBV infection. The dynamic nomogram model has better predictive accuracy and discriminative ability. In addition, it can be used for individual risk estimation at the point of diagnosis for NSCLC patients with HBV infection, which can aid in the decision-making process in clinical practice.

The dynamic nomogram included TNM stage, treatment, CRP, and PLT. Currently, the Union Internationale Contre le Cancer/American Joint Cancer Committee (UICC/AJCC) TNM staging system is widely used as a guide for estimating prognosis, and it is the basis for treatment decisions of various solid tumors. However, the classification is only based on the anatomical extent of the disease, which doesn\'t fully reflect the biological heterogeneity of NSCLC patients, and other risk factors were not taken into account in the systems. Thus, the traditional TNM staging system may not accurately predict the OS for NSCLC patients. Integration of the TNM staging system with other risk factors could be highly predictive of OS in NSCLC patients with HBV infection. Interestingly, our results indicated that the C-index of the current dynamic nomogram (0.76) was higher than the traditional TNM staging system (0.70). Also, the decision curve analysis for 3- and 5-year survival revealed a better predictive accuracy of the dynamic nomogram than TNM staging system. We previously had reported that a nomogram model for NSCLC patients with chronic hepatitis B viral infection based on the prognostic factors of liver function indicators[@B21]. Considering the systemic inflammation has been linked with poor prognosis in patients with cancer. So, in this study, we only focus on the prognosis of inflammation-based factors for NSCLC with HBV infection, and propose a nomogram model for NSCLC patients with HBV infection. We compared current nomogram model with previous model, the predictive accuracy of the current nomogram keeping almost the same accuracy as previous one. The C-index of current nomogram was 0.76, and previous reported nomogram was 0.77. There was no statistical difference between the two nomogram models. But the current nomogram included less prognostic factors (4 vs 8). So current nomogram model maybe more convenient for clinical applications.

CRP is an acute-phase protein that plays important roles in protecting tissue from inflammation, and it is a simple and reproducible systemic inflammation marker. Many studies have reported that the level of CRP is related to the prognosis of various cancers[@B13]-[@B14], [@B25]-[@B26]. CRP production can be caused by interleukin (IL)-6. IL-6 as an important proinflammatory cytokine that could promote cancer growth and metastasis through Janus kinase (JAK)-signal transducer and activator of transcription (STAT) 3 activation. Thus, CRP could be a marker of IL-6/JAK/STAT3-induced tumor progression[@B27]. PLT is associated with systemic inflammation and cancerous diseases, which have emerged as central players in the progression of cancer and local responses to tumor growth[@B28]. Within the blood circulation system, PLT could protect cancer cells from immune elimination and promote their arrest in the endothelium. This supports the establishment of secondary lesions, which contributes to cancer cell survival and migration[@B29]. Our results were consistent with previously reported findings.

The univariate analysis revealed that ALB, NLR, PLR, and PNI were all associated with OS, but the multivariate analysis results indicated that they were not independently associated with OS. These results were contrary to previously reported findings[@B17], [@B30]-[@B35]. A possible explanation is that our continuous variables were transformed into high and low groups based on the cut-off values of the X-tile program, which was different from other reports. A second possible explanation is that previous studies have reported that chronic HBV infection was associated with poor prognosis in patients with NSCLC[@B7], so NSCLC patients with HBV infection have different clinicopathological characteristics compared to those without HBV infection. This may be the most important reason that leads to differing results from other reports.

We further divided the patients into three risk groups based on TPS. The survival curves separated very well in the patients (*P* \< 0.001), and our results indicated that a higher TPS was associated with a shorter OS in NSCLC patients with HBV infection. Consequently, patients with high TPS in high-risk groups should receive special attention and active surveillance.

There were certain limitations in our study. First, this study was typical of retrospective analyses, so the retrospective nature of this study cannot exclude all potential biases. Second, many studies were adopted major three methods to determine the cut-off values of prognostic factors: a: median[@B36]; b: X-tile tool[@B20], [@B37]; c: ROC method[@B38]-[@B39]. The cut-off values of each method were determined by the analyzed patients data, which leading different analyzed patients data had different cut-off values in the same prognostic factor. In our study, the cut-off values of some prognostic factors were determined by using X-tile tool. The best way to solve this problem was to validate the results using external data. Thirdly, the database used to generate the dynamic nomogram consisted of patient data from a single cancer center, and the sample sizes were small. Further larger scale and multi-center studies should be performed to externally validate the dynamic nomogram and to verify whether our results were suitable for the general population. At last, this study only focused on the impact of inflammation-based prognostic factors on the prognosis of NSCLC patients with HBV infection; other traditional prognostic factors, such as cytokeratin 19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), epidermal growth factor receptor (EGFR), and CA125 were not analyzed in this study[@B40]-[@B43]. Furthermore, previous studies have reported that serum HBV-DNA at diagnosis is an independent and significant prognostic factor in hepatocellular carcinoma[@B44]. However, measuring HBV-DNA was not common practice in our cancer center. Thus, whether HBV DNA levels were associated with the prognosis in NSCLC patients with HBV infection should be further explored.

In summary, the dynamic nomogram was a simple and inexpensive prognostic tool for NSCLC patients with HBV infection, and it has better predictive accuracy and discriminative ability. It could aid clinicians in the decision-making process in clinical practice.
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###### 

Patient demographics and clinical characteristics

  --------------------------------------------
  Characteristic               No.      \%
  ---------------------------- ----- -- ------
  **Gender**                            

  Male                         155      76.4

  Female                       48       23.6

  **Age(years)**                        

  ≤42                          27       13.3

  \>42                         176      86.7

  **Family history**                    

  Yes                          47       23.2

  No                           156      76.8

  **Smoking behavior^a^**               

  Yes                          122      60.1

  No                           81       39.9

  **TNM stage^b^**                      

  I                            44       21.7

  II                           23       11.3

  III                          73       36.0

  IV                           63       31.0

  **Histological type**                 

  Adenocarcinoma               129      63.6

  Squamous cell carcinoma      65       32.0

  Other                        9        4.4

  **Size(cm)^c^**                       

  ≤6.0                         164      80.8

  \>6.0                        39       19.2

  **Treatment**                         

  Surgery                      47       23.2

  Surgery and Radiotherapy/\   65       32.0
  Chemotherapy                          

  Radiotherapy/Chemotherapy    69       34.0

  Other                        22       10.8

  **ALB(g/L)**                          

  ≤37.6                        26       12.8

  \>37.6                       177      87.2

  **CRP(mg/L)**                         

  ≤9.5                         135      66.5

  \>9.5                        68       33.5

  **WBC(10\^^9^/L)**                    

  ≤10.0                        170      83.7

  \>10.0                       33       16.3

  **Neutrophil(10\^^9^/L)**             

  ≤7.5                         175      86.2

  \>7.5                        28       13.8

  **Lymphocyte(10\^^9^/L)**             

  ≤1.8                         80       39.4

  \>1.8                        123      60.6

  **Platelet(10\^^9^/L)**               

  ≤163                         26       12.8

  \>163                        177      87.2

  **NLR**                               

  ≤4.30                        177      87.2

  \>4.30                       26       12.8

  **PLR**                               

  ≤109.5                       84       41.4

  \>109.5                      119      58.6

  **PNI**                               

  ≤48.1                        39       19.2

  \>48.1                       164      80.8
  --------------------------------------------

a: Cigarette smoking is defined as having at least 1 cigarette per day for at least 6 months[@B24].

b: TNM stage was classified according to the AJCC 7th TNM staging system.

c: The tumor maximum diameter.

Abbreviations: TNM: Pathological Tumour Node Metastasis stage; ALB: albumin; CRP: C-reactive protein; WBC: white blood cell; NLR: neutrophil/lymphocyte ratio; PLR: platelet/lymphocyte ratio; PNI: prognostic nutritional index.

###### 

Univariate and multivariate Cox proportional hazards regression analysis for OS

  -----------------------------------------------------------------------------------------------------------------
  Variable                     Univariate analysis             Multivariate analysis                      
  ---------------------------- --------------------- --------- ----------------------- ------------------ ---------
  **Gender**                                                                           \-                 \-

  Male                         Reference                                                                  

  Female                       0.85 (0.53-1.36)      0.495                                                

  **Age(years)**                                                                       \-                 \-

  ≤42                          Reference                                                                  

  \>42                         0.32 (0.19-0.53)      \<0.001                                              

  **Family history**                                                                   \-                 \-

  Yes                          Reference                                                                  

  No                           0.92 (0.58-1.46)      0.735                                                

  **Smoking behavior**                                                                 \-                 \-

  Yes                          Reference                                                                  

  No                           1.03 (0.69-1.53)      0.901                                                

  **TNM stage**                                                                        1.40 (1.06-1.86)   0.019

  I                            Reference                                                                  

  II                           1.08 (0.40-2.87)      0.885                                                

  III                          2.75 (1.43-5.30)      0.003                                                

  IV                           6.61 (3.35-12.72)     \<0.001                                              

  **Histological type**                                                                \-                 \-

  Adenocarcinoma               Reference                                                                  

  Squamous\                    0.89 (0.58-1.38)      0.603                                                
  cell carcinoma                                                                                          

  Other                        1.68 (0.68-4.17)      0.265                                                

  **Size(cm)**                                                                         \-                 \-

  ≤6.0                         Reference                                                                  

  \>6.0                        2.35 (1.50-3.70)      \<0.001                                              

  **Treatment**                                                                        1.76 (1.28-2.40)   \<0.001

  Surgery                      Reference                                                                  

  Surgery and Radiotherapy/\   0.91 (0.47-1.74)      0.772                                                
  Chemotherapy                                                                                            

  Radiotherapy/\               3.80 (2.11-6.84)      \<0.001                                              
  Chemotherapy                                                                                            

  Other                        6.99 (3.47-14.06)     \<0.001                                              

  **ALB(g/L)**                                                                         \-                 \-

  ≤37.6                        Reference                                                                  

  \>37.6                       0.40 (0.25-0.66)      \<0.001                                              

  **CRP(mg/L)**                                                                        1.76 (1.09-2.84)   0.020

  ≤9.5                         Reference                                                                  

  \>9.5                        2.70 (1.81-4.03)      \<0.001                                              

  **WBC (10\^^9^/L)**                                                                  \-                 \-

  ≤10.0                        Reference                                                                  

  \>10.0                       1.92 (1.17-3.14)      0.009                                                

  **Neutrophil(10\^^9^/L)**                                                            \-                 \-

  ≤7.5                         Reference                                                                  

  \>7.5                        2.66 (1.61-4.40)      \<0.001                                              

  **Lymphocyte(/10\^^9^/L)**                                                           \-                 \-

  ≤1.8                         Reference                                                                  

  \>1.8                        0.80 (0.54-1.19)      0.268                                                

  **Platelet(10\^^9^/L)**                                                              0.43 (0.22-0.83)   0.012

  ≤163                         Reference                                                                  

  \>163                        0.50 (0.30-0.84)      0.009                                                

  **NLR**                                                                              \-                 \-

  ≤4.30                        Reference                                                                  

  \>4.30                       3.30 (1.96-5.55)      \<0.001                                              

  **PLR**                                                                              \-                 \-

  ≤109.5                       Reference                                                                  

  \>109.5                      1.57 (1.04-2.38)      0.034                                                

  **PNI**                                                                              \-                 \-

  ≤48.1                        Reference                                                                  

  \>48.1                       0.40 (0.26-0.63)      \<0.001                                              
  -----------------------------------------------------------------------------------------------------------------

###### 

The C-index of current nomogram, reported nomogram and TNM stage for prediction of OS\*

  Factor                                  C-index (95% CI)    *p*
  --------------------------------------- ------------------- ---------
  Current nomogram\*                      0.76 ( 0.72-0.80)   
  Reported nomogram                       0.77 (0.73-0.81)    
  TNM stage                               0.70 ( 0.66-0.74)   
  Current nomogram vs TNM stage                               \<0.001
  Reported nomogram vs TNM stage                              \<0.001
  Current nomogram vs Reported nomogram                       0.67

\* Current nomogram: including eight risk factors (age, TNM, treatment, CRP and PLT).

C-index = concordance index; CI = confidence interval.
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